Corsair Pharma Reports Successful Phase 1 Trial for TRX-248 Patch in Pulmonary Arterial Hypertension
Corsair Pharma Announces Positive Phase 1 Results for the TRX-248 Transdermal System in Pulmonary Arterial Hypertension
Image: Businesswire
Corsair Pharma has announced positive results from its Phase 1 clinical trial for the TRX-248 Transdermal System, a once-daily patch for treating pulmonary arterial hypertension (PAH). The trial demonstrated steady treprostinil levels and acceptable safety, paving the way for further development of this innovative treatment.
- 01The Phase 1 trial involved nine female volunteers and focused on the safety and pharmacokinetics of the TRX-248 patch.
- 02The transdermal system achieved steady treprostinil plasma levels over 24 hours with low fluctuations.
- 03Corsair's patch aims to provide a convenient, noninvasive alternative to current treprostinil delivery methods.
- 04The prostacyclin market for PAH treatments is valued at approximately $3.3 billion annually, with treprostinil accounting for about $2 billion.
- 05The TRX-248 system may address significant unmet medical needs for PAH patients who struggle with existing therapies.
Advertisement
In-Article Ad
Corsair Pharma, based in Newark, California, has successfully completed a Phase 1 clinical trial for its TRX-248 Transdermal System, designed to treat pulmonary arterial hypertension (PAH). The trial involved nine female participants and assessed the safety and pharmacokinetics of the once-daily transdermal patch. Results indicated that the TRX-248 system maintained steady and therapeutically relevant blood levels of treprostinil, a key drug for PAH treatment, with low peak-to-trough fluctuations. This transdermal method could provide a more convenient and effective alternative to current delivery systems, which often present challenges for patients. The trial's positive outcomes support the potential for further clinical development. With the prostacyclin market generating over $3.3 billion in annual sales in the U.S., Corsair's innovative approach could significantly improve the quality of life for PAH patients who are unable or unwilling to use existing therapies.
Advertisement
In-Article Ad
The successful development of the TRX-248 Transdermal System could provide a new treatment option for PAH patients, potentially improving their quality of life.
Advertisement
In-Article Ad
Reader Poll
What do you think about the potential of transdermal treatments for PAH?
Connecting to poll...
Read the original article
Visit the source for the complete story.